公开(公告)号：US12077820B2

公开(公告)日：2024-09-03

申请号：US16636162

申请日：2018-08-03

Applicant: OSE IMMUNOTHERAPEUTICS ,  CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

Inventor： Nicolas Poirier ,  Richard Danger

IPC: C12Q1/68 ,  C07K16/24 ,  C07K16/28 ,  C12P19/34 ,  C12Q1/6883 ,  G01N33/543

CPC classification number: C12Q1/6883 ,  C07K16/241 ,  C07K16/2839 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/543 ,  G01N2800/065

Abstract: The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TN-Falpha agents, for treatment with anti-α4β7 agents or with both anti-TNFalpha agent and anti-α4β7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-α4β7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease. The invention describes a method of in vitro assessing whether a treatment with anti-TNFalpha agent or with anti-α4β7 agent may be useful in a human patient suffering from inflammatory condition or disease, in particular when said condition or disease is a chronic and/or relapsing one, particularly a gastrointestinal, more particularly intestinal, inflammatory condition or disease which is eligible for treatment with anti-TNFalpha agent or respectively with anti-α4β7 agent. In a specific embodiment the method is suitable to assess whether such patient would be non-responsive to treatment with such anti-TNFalpha agent or respectively with anti-α4β7 agent and comprising determining a molecular signature in a biological sample previously obtained from said human patient.

公开(公告)号：US12054549B2

公开(公告)日：2024-08-06

申请号：US18050817

申请日：2022-10-28

Applicant: Merck Patent GmbH

Inventor： Ilhan Celik ,  Eike Staub ,  Miriam Urban ,  Sabine Raab-Westphal ,  Eileen Samy ,  Andrew Bender ,  Georgianna Varrone ,  Yin Wu ,  Daigen Xu

IPC: A61K39/00 ,  A61K39/395 ,  A61P11/00 ,  A61P17/02 ,  C07K16/28 ,  C12Q3/00 ,  G01N33/543

CPC classification number: C07K16/2848 ,  A61K39/395 ,  A61P11/00 ,  A61P17/02 ,  C07K16/2839 ,  C12Q3/00 ,  G01N33/54366 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76

Abstract: A method can treat a patient suffering from at least one of fibrosis and a fibrotic disorder. The method includes administering a therapeutically effective amount of an anti-αv integrin antibody DI17E6, or a biologically active variant or modification thereof, to the patient.

公开(公告)号：US20240182581A1

公开(公告)日：2024-06-06

申请号：US18344724

申请日：2023-06-29

Applicant: Millennium Pharmaceuticals, Inc.

Inventor： Maria Rosario ,  Michael David Laurence Smyth

IPC: C07K16/28 ,  A61K31/496 ,  A61K39/00 ,  A61K39/395 ,  A61P1/00

CPC classification number: C07K16/2839 ,  A61K31/496 ,  A61K39/3955 ,  A61P1/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24

Abstract: The invention provides methods for the treatment of chronic pouchitis comprising administering an anti-α4β7 antibody, e.g., vedolizumab, to a human subject in need thereof.

公开(公告)号：US11913073B2

公开(公告)日：2024-02-27

申请号：US18185153

申请日：2023-03-16

Applicant: PML Screening, LLC ,  The Université Paris-Saclay ,  The Assistance Publique—Hôpitaux de Paris (APHP) ,  The Institut National de la Santé et de la Recherche Médicale (INSERM)

Inventor： Eli Hatchwell ,  Peggy S. Eis ,  Edward B. Smith, III ,  Yassine Taoufik

IPC: C12Q1/6883 ,  A61K39/00 ,  C07K16/28 ,  G01N33/569

CPC classification number: C12Q1/6883 ,  C07K16/2839 ,  G01N33/56983 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  G01N2333/025 ,  G01N2800/065 ,  G01N2800/285 ,  G01N2800/52

Abstract: This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

公开(公告)号：US11827709B2

公开(公告)日：2023-11-28

申请号：US17112533

申请日：2020-12-04

Applicant: SEAGEN INC.

Inventor： Maureen Ryan ,  Lori Westendorf ,  Eric Bradley Meyer ,  Heather Jean Kostner

IPC: C07K16/28 ,  A61K47/68 ,  A61K38/07 ,  A61K47/54 ,  A61K45/06 ,  A61P35/00 ,  A61K47/65

CPC classification number: C07K16/2839 ,  A61K38/07 ,  A61K45/06 ,  A61K47/545 ,  A61K47/65 ,  A61K47/6803 ,  A61K47/6849 ,  A61P35/00 ,  C07K2317/24

Abstract: Provided are novel anti-αvβ6 antibodies and antibody-drug conjugates and methods of using such anti-αvβ6 antibodies and antibody-drug conjugates to treat cancer.

公开(公告)号：US11819550B2

公开(公告)日：2023-11-21

申请号：US17067058

申请日：2020-10-09

Applicant: EAGLE BIOLOGICS, INC.

Inventor： Alyssa M. Larson ,  Alisha K. Weight ,  Kevin Love ,  Alan Crane ,  Robert S. Langer ,  Alexander M. Klibanov

IPC: A61K39/395 ,  A61K47/06 ,  A61K9/19 ,  C07K16/32 ,  A61K47/24 ,  A61K9/00 ,  A61K47/20 ,  A61K47/22 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  A61K38/00

CPC classification number: A61K47/06 ,  A61K9/0019 ,  A61K9/19 ,  A61K39/3955 ,  A61K47/20 ,  A61K47/22 ,  A61K47/24 ,  C07K16/22 ,  C07K16/241 ,  C07K16/2839 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  A61K38/00

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.

公开(公告)号：US20230349923A1

公开(公告)日：2023-11-02

申请号：US18212542

申请日：2023-06-21

Applicant: Maximus Diagnostic Technologies, LLC

Inventor： Julia J. Liu

IPC: G01N33/68 ,  C07K16/24 ,  C07K16/28 ,  A61P1/00 ,  A61K31/4035 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/496 ,  A61K31/519

CPC classification number: G01N33/6893 ,  C07K16/241 ,  C07K16/2839 ,  A61P1/00 ,  A61K31/4035 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/496 ,  A61K31/519 ,  G01N2800/065 ,  G01N2800/52 ,  C07K2317/24 ,  A61K2039/55

Abstract: In some embodiments, the invention provides a method for identifying an agent beneficial to treat a patient with inflammatory bowel disease comprising: a) determining a status of an intestinal barrier in the patient; and b) categorizing the status as severe dysfunction or moderate dysfunction, wherein a patient categorized as having severe dysfunction is identified as a patient who will benefit from treatment with an agent selected from the group consisting of an anti-TNF agent and/or an anti-IL-12/23 agent, and a patient categorized as having moderate dysfunction is identified as a patient who will benefit from treatment with an anti-integrin agent, an anti-janus kinase agent, and/or and a sphingosine-1-phosphate receptor agonist agent.

公开(公告)号：US11802156B2

公开(公告)日：2023-10-31

申请号：US17338991

申请日：2021-06-04

Applicant: Pfizer Inc.

Inventor： Karin Anderson

IPC: C07H21/04 ,  C12P21/06 ,  C12N1/20 ,  C12N15/74 ,  C07K16/28 ,  A61P29/00 ,  A61P37/06 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61P29/00 ,  A61P37/06 ,  A61K2039/505 ,  C07K16/2839 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present disclosure relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The disclosure also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The disclosure also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The disclosure also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present disclosure also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The disclosure also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The disclosure also relates to transgenic animals or plants comprising nucleic acid molecules of the disclosure.

公开(公告)号：US20230338519A1

公开(公告)日：2023-10-26

申请号：US17998693

申请日：2021-05-14

Applicant: Transmed Gothenburg AB

Inventor： Nils Lycke ,  Mohammad Arabpour ,  Fredrik Höök

IPC: A61K39/39 ,  C07K16/28 ,  C07K14/28 ,  A61P37/04 ,  A61K39/145

CPC classification number: A61K39/39 ,  C07K16/2839 ,  C07K14/28 ,  A61P37/04 ,  A61K39/145 ,  C07K2317/622 ,  C07K2319/55 ,  A61K2039/505

Abstract: The present invention relates to a fusion protein, a nucleotide sequence encoding such a fusion protein, the use thereof as an adjuvant or vaccine. The fustin protein comprises a bacterial exotoxin and a single chain antibody fragment (scFv) that specifically binds to a surface marker on dendritic cells. The fusion protein is advantageously administered intranasally, orally or intrapulmonarily.

公开(公告)号：US20230312727A1

公开(公告)日：2023-10-05

申请号：US18046450

申请日：2022-10-13

Applicant: Millennium Pharmaceuticals, Inc.

Inventor： Willow Diluzio ,  Phoung M. Nguyen ,  Csanad M. Varga ,  Vaithianathan Palaniappan ,  Jason Brown ,  Irving H. Fox ,  Catherine Scholz ,  Erica Helen Jenkins ,  Maria Rosario

IPC: C07K16/28 ,  A61K9/00 ,  A61K47/12 ,  A61K47/14 ,  A61K47/18 ,  A61K47/26 ,  A61K39/395

CPC classification number: C07K16/2839 ,  A61K9/0019 ,  A61K47/12 ,  A61K47/14 ,  A61K47/183 ,  A61K47/26 ,  A61K39/39591 ,  A61K2039/505

Abstract: Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.